lilly glp-1 drugs Novo, buoyed by fast-growing drug sales glp 1 zepbound Eli Lilly's

GLP-1 Receptor Agonist Market size is growing with a CAGR of 12.5% in the prediction period and it crosses USD 72.33 Bn by 2033 from USD 31.71 Bn in 2026.

A Breakthrough Award, New Evidence in Parkinson's and Heart Disease

Major market players have adopted organic and inorganic strategies, including partnerships and investments

Over the past six months, states have been proactive in their consideration or reconsideration of next steps pertaining to coverage of Glucagon-like Peptide (GLP)-1s weight loss medication

Over the past year, more patients have come to us asking about Ozempic (semaglutide) and similar GLP-1 receptor agonists for their role in weight loss but also for effects on []

This study aims to comprehensively review the impact of GLP-1 RAs on various body systems, emphasizing both positive and negative effects while addressing existing knowledge gaps in the literature